Iena Plastic Surgery Clinic, Paris, France.
Rzany and Hund, Berlin, Germany.
Aesthet Surg J. 2020 Aug 14;40(9):1000-1008. doi: 10.1093/asj/sjz248.
The FACE-Q patient-reported outcome assesses patient experiences/outcomes with aesthetic facial procedure. A recent trial of abobotulinumtoxinA (ASI, liquid formulation) was the first to our knowledge to assess satisfaction with FACE-Q after glabellar line (GL) injection.
The authors sought to evaluate patient satisfaction with ASI for GL treatment employing 3 FACE-Q scales: facial appearance, psychological well-being, and aging appearance.
This was a Phase 3, randomized, double-blind, placebo-controlled trial (NCT02353871) of ASI 50 units in adults with moderate-to-severe GL with 6-month follow-up.
Significantly greater least squares mean changes from baseline were associated with ASI treatment (N = 125) vs placebo (N = 59) for satisfaction with facial appearance at all visits until day 148 (5 months; P < 0.0001-0.0037), psychological well-being at all visits (P < 0.0001-0.0279), and aging appearance at all visits except day 148 (P < 0.0001-0.0409). Significant differences (ASI vs placebo) were observed at all visits for individual items: "how rested your face looks" (P < 0.0001-0.0415), "I feel okay about myself" (P = 0.0011-0.0399), and "I feel attractive" (P < 0.0001-0.0102). Maximal least squares mean (standard error) changes in aging appearance score were -1.4 (0.3; ASI) and -0.3 (0.4; placebo). Investigators' live assessment of GL at maximum frown significantly correlated with improvements in FACE-Q facial appearance and psychological scales (all patients: r = -0.41 and r = -0.36 [both P < 0.0001], respectively).
Significant improvements in patient satisfaction with aging, facial appearance, and, importantly, psychological well-being were demonstrated with ASI employing FACE-Q scales up to 5 to 6 months post-injection. Results support a long duration of efficacy with ASI and use of FACE-Q in future trials and clinical practice.
FACE-Q 患者报告结局评估了患者对面部美容程序的体验/结果。最近一项关于 abobotulinumtoxinA（ASI，液体配方）的试验是我们所知的第一个评估皱眉线（GL）注射后对 FACE-Q 满意度的试验。
作者旨在通过 3 个 FACE-Q 量表评估 ASI 治疗 GL 的患者满意度：面部外观、心理幸福感和衰老外观。
这是一项为期 6 个月的 III 期、随机、双盲、安慰剂对照试验（NCT02353871），评估 ASI 50 单位治疗中重度 GL 的成年人。
与安慰剂相比，在所有随访访视中，接受 ASI 治疗（N = 125）的患者在所有随访访视中（直至第 148 天，即 5 个月；P < 0.0001-0.0037）、心理幸福感（P < 0.0001-0.0279）和衰老外观（除第 148 天外，P < 0.0001-0.0409）的面部外观满意度最小平方均数变化具有统计学意义。在所有随访访视中，除了第 148 天（P < 0.0001-0.0415）外，个别项目的差异（ASI 与安慰剂）均具有统计学意义：“你的面部看起来有多休息”（P < 0.0001-0.0415）、“我对自己感觉良好”（P = 0.0011-0.0399）和“我觉得自己有吸引力”（P < 0.0001-0.0102）。衰老外观评分的最大最小平方均数（标准误差）变化为-1.4（0.3；ASI）和-0.3（0.4；安慰剂）。研究人员对最大皱眉时 GL 的现场评估与 FACE-Q 面部外观和心理量表的改善显著相关（所有患者：r = -0.41 和 r = -0.36 [均 P < 0.0001]）。
接受 ASI 治疗的患者在衰老、面部外观以及重要的心理幸福感方面的满意度显著提高，在注射后 5 至 6 个月时可观察到。结果支持 ASI 的疗效持续时间长，并在未来的试验和临床实践中使用 FACE-Q。
